iCAD (NASDAQ:ICAD – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect iCAD to post earnings of ($0.05) per share and revenue of $4.72 million for the quarter.
iCAD Trading Up 5.0 %
iCAD stock opened at $2.32 on Thursday. iCAD has a 12 month low of $1.18 and a 12 month high of $3.78. The stock’s 50 day simple moving average is $2.61 and its two-hundred day simple moving average is $2.03. The firm has a market cap of $61.57 million, a PE ratio of -17.85 and a beta of 1.95.
Analyst Ratings Changes
Separately, StockNews.com upgraded iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, February 20th.
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
See Also
- Five stocks we like better than iCAD
- Breakout Stocks: What They Are and How to Identify Them
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Top Stocks Investing in 5G Technology
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
